161 related articles for article (PubMed ID: 32172641)
1. The challenge of checkpoint inhibitors in prostate cancer: drugs for the many but useful to a few.
F Slovin S
Immunotherapy; 2020 Mar; 12(4):219-221. PubMed ID: 32172641
[No Abstract] [Full Text] [Related]
2. Immune Escape in Prostate Cancer: Known and Predicted Mechanisms and Targets.
Reva BA; Omelchenko T; Nair SS; Tewari AK
Urol Clin North Am; 2020 Nov; 47(4S):e9-e16. PubMed ID: 33446324
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for immune checkpoint inhibitors in selected rare subtypes of soft tissue sarcoma?
Assi T; Cesne AL; Mir O
Immunotherapy; 2021 Feb; 13(2):91-93. PubMed ID: 33291976
[No Abstract] [Full Text] [Related]
4. Immunotherapy in treatment of metastatic prostate cancer: An approach to circumvent immunosuppressive tumor microenvironment.
Sun BL
Prostate; 2021 Nov; 81(15):1125-1134. PubMed ID: 34435699
[TBL] [Abstract][Full Text] [Related]
5. Elucidating Durable Responses to Immune Checkpoint Inhibition.
Rescigno P; Aversa C; Crespo M; Seed G; Lambros M; Gurel B; Figueiredo I; Bianchini D; Riisnaes R; Pereira R; Fenor de la Maza MD; Carmichael J; Chandran K; Ferreira A; Bertan C; Paschalis A; Curcean A; Sharp A; Yuan W; Tunariu N; Poehlein C; Carreira S; de Bono JS
Eur Urol; 2020 Oct; 78(4):639-641. PubMed ID: 32653323
[No Abstract] [Full Text] [Related]
6. Immune Checkpoint Inhibition in Prostate Cancer.
Nicholson LT; Fong L
Trends Cancer; 2020 Mar; 6(3):174-177. PubMed ID: 32101720
[TBL] [Abstract][Full Text] [Related]
7. Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockade.
Sena LA; Salles DC; Engle EL; Zhu Q; Tukachinsky H; Lotan TL; Antonarakis ES
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34140335
[TBL] [Abstract][Full Text] [Related]
8. Current status of immunotherapy for advanced gastric cancer.
Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?
de Almeida DVP; Fong L; Rettig MB; Autio KA
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-18. PubMed ID: 32343604
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab: a new standard of care in metastatic colorectal cancer.
Saleh K; Kordahi M; Felefly T; Khalife N
Immunotherapy; 2021 Oct; 13(15):1245-1247. PubMed ID: 34542319
[No Abstract] [Full Text] [Related]
11. Maintenance avelumab in metastatic bladder cancer as a step towards sequencing immunotherapy.
Samaha H; Samaha R; Sarkis J; Kattan J
Immunotherapy; 2021 Mar; 13(4):271-275. PubMed ID: 33397137
[No Abstract] [Full Text] [Related]
12. Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
Kurnit KC; Reid P; Moroney JW; Fleming GF
Gynecol Oncol; 2020 Sep; 158(3):531-537. PubMed ID: 32641238
[TBL] [Abstract][Full Text] [Related]
13. Understanding the tumor-immune microenvironment in prostate cancer.
Dong L; Myers KV; Pienta KJ
Curr Opin Oncol; 2021 May; 33(3):231-237. PubMed ID: 33606403
[TBL] [Abstract][Full Text] [Related]
14. [Immunotherapy with PD-1 and PD-L1 inhibitors for prostate cancer].
Huang L; He J
Zhonghua Nan Ke Xue; 2020 Nov; 26(10):944-948. PubMed ID: 33382229
[TBL] [Abstract][Full Text] [Related]
15. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
[No Abstract] [Full Text] [Related]
16. Complete and durable response to immune checkpoint inhibitor in a patient with refractory and metastatic hepatoblastoma.
Tsai HL; Yeh YC; Yu TY; Lee CY; Hung GY; Yeh YT; Liu CS; Yen HJ
Pediatr Hematol Oncol; 2021 May; 38(4):385-390. PubMed ID: 33641599
[TBL] [Abstract][Full Text] [Related]
17. Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review.
Kim TJ; Koo KC
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751945
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
[TBL] [Abstract][Full Text] [Related]
20. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
